My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 337

    1.

    Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

    Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A; Study 907 Team.

    Ann Intern Med. 2003 Sep 2;139(5 Pt 1):313-20.PMID: 12965939 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

    Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD.

    J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21.PMID: 12792350 [PubMed - indexed for MEDLINE]Related articles

    3.

    Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group.

    JAMA. 2004 Jul 14;292(2):191-201.PMID: 15249568 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

    Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK; Study 902 Team.

    AIDS. 2002 Jun 14;16(9):1257-63.PMID: 12045491 [PubMed - indexed for MEDLINE]Related articles

    5.

    Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.

    Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL.

    Pediatrics. 2005 Dec;116(6):e846-54. Epub 2005 Nov 15.PMID: 16291735 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.

    McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD.

    J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1340-50.PMID: 15483463 [PubMed - indexed for MEDLINE]Related articles

    7.

    Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

    Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD.

    AIDS. 2002 Jun 14;16(9):1227-35.PMID: 12045487 [PubMed - indexed for MEDLINE]Related articles

    8.

    Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.

    Fung HB, Stone EA, Piacenti FJ.

    Clin Ther. 2002 Oct;24(10):1515-48. Review.PMID: 12462284 [PubMed - indexed for MEDLINE]Related articles

    9.

    Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

    Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M.

    J Infect Dis. 2004 Mar 1;189(5):837-46. Epub 2004 Feb 10.PMID: 14976601 [PubMed - indexed for MEDLINE]Related articles

    10.

    Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

    Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM.

    J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):450-8.PMID: 11511821 [PubMed - indexed for MEDLINE]Related articles

    11.

    Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

    Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS; ESS30009 Study.

    J Infect Dis. 2005 Dec 1;192(11):1921-30. Epub 2005 Oct 25.PMID: 16267763 [PubMed - indexed for MEDLINE]Related articles

    12.

    Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.

    Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.

    J Med Virol. 2007 Feb;79(2):105-10.PMID: 17177308 [PubMed - indexed for MEDLINE]Related articles

    13.

    Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

    Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D, Toole JJ, Coakley D.

    JAMA. 1999 Dec 22-29;282(24):2305-12.PMID: 10612317 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

    Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM; Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group.

    Antivir Ther. 2006;11(2):213-21.PMID: 16640102 [PubMed - indexed for MEDLINE]Related articles

    15.

    Tenofovir disoproxil fumarate.

    Chapman T, McGavin J, Noble S.

    Drugs. 2003;63(15):1597-608. Review.PMID: 12887265 [PubMed - indexed for MEDLINE]Related articles

    16.

    Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK; 903 Study Team; 907 Study Team.

    J Infect Dis. 2004 Apr 1;189(7):1185-92. Epub 2004 Mar 12.PMID: 15031786 [PubMed - indexed for MEDLINE]Related articles

    17.

    Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

    Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.

    J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40.PMID: 17057609 [PubMed - indexed for MEDLINE]Related articles

    18.

    Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.

    DART Virology Group and Trial Team.

    AIDS. 2006 Jun 26;20(10):1391-9.PMID: 16791013 [PubMed - indexed for MEDLINE]Related articles

    19.

    Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

    Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team.

    JAMA. 2002 Jul 10;288(2):169-80.PMID: 12095381 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team.

    AIDS. 2009 Jul 31;23(12):1547-56.PMID: 19542866 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity